Cargando…
Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborn...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063779/ https://www.ncbi.nlm.nih.gov/pubmed/21455295 http://dx.doi.org/10.1371/journal.pone.0017883 |
_version_ | 1782200829723279360 |
---|---|
author | Pang, Yuan-Ping Park, Jewn Giew Wang, Shaohua Vummenthala, Anuradha Mishra, Rajesh K. McLaughlin, John E. Di, Rong Kahn, Jennifer Nielsen Tumer, Nilgun E. Janosi, Laszlo Davis, Jon Millard, Charles B. |
author_facet | Pang, Yuan-Ping Park, Jewn Giew Wang, Shaohua Vummenthala, Anuradha Mishra, Rajesh K. McLaughlin, John E. Di, Rong Kahn, Jennifer Nielsen Tumer, Nilgun E. Janosi, Laszlo Davis, Jon Millard, Charles B. |
author_sort | Pang, Yuan-Ping |
collection | PubMed |
description | Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborne diseases with significant morbidity and mortality. Ricin, produced by the castor bean plant, is another RIP lethal to mammals. Currently, no US Food and Drug Administration-approved vaccines nor therapeutics exist to protect against ricin, Shiga-like toxins, or other RIPs. Development of effective small-molecule RIP inhibitors as therapeutics is challenging because strong electrostatic interactions at the RIP•SRL interface make drug-like molecules ineffective in competing with the rRNA for binding to RIPs. Herein, we report small molecules that show up to 20% cell protection against ricin or Stx2 at a drug concentration of 300 nM. These molecules were discovered using the doorstop approach, a new approach to protein•polynucleotide inhibitors that identifies small molecules as doorstops to prevent an active-site residue of an RIP (e.g., Tyr80 of ricin or Tyr77 of Stx2) from adopting an active conformation thereby blocking the function of the protein rather than contenders in the competition for binding to the RIP. This work offers promising leads for developing RIP therapeutics. The results suggest that the doorstop approach might also be applicable in the development of other protein•polynucleotide inhibitors as antiviral agents such as inhibitors of the Z-DNA binding proteins in poxviruses. This work also calls for careful chemical and biological characterization of drug leads obtained from chemical screens to avoid the identification of irrelevant chemical structures and to avoid the interference caused by direct interactions between the chemicals being screened and the luciferase reporter used in screening assays. |
format | Text |
id | pubmed-3063779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-30637792011-03-31 Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach Pang, Yuan-Ping Park, Jewn Giew Wang, Shaohua Vummenthala, Anuradha Mishra, Rajesh K. McLaughlin, John E. Di, Rong Kahn, Jennifer Nielsen Tumer, Nilgun E. Janosi, Laszlo Davis, Jon Millard, Charles B. PLoS One Research Article Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborne diseases with significant morbidity and mortality. Ricin, produced by the castor bean plant, is another RIP lethal to mammals. Currently, no US Food and Drug Administration-approved vaccines nor therapeutics exist to protect against ricin, Shiga-like toxins, or other RIPs. Development of effective small-molecule RIP inhibitors as therapeutics is challenging because strong electrostatic interactions at the RIP•SRL interface make drug-like molecules ineffective in competing with the rRNA for binding to RIPs. Herein, we report small molecules that show up to 20% cell protection against ricin or Stx2 at a drug concentration of 300 nM. These molecules were discovered using the doorstop approach, a new approach to protein•polynucleotide inhibitors that identifies small molecules as doorstops to prevent an active-site residue of an RIP (e.g., Tyr80 of ricin or Tyr77 of Stx2) from adopting an active conformation thereby blocking the function of the protein rather than contenders in the competition for binding to the RIP. This work offers promising leads for developing RIP therapeutics. The results suggest that the doorstop approach might also be applicable in the development of other protein•polynucleotide inhibitors as antiviral agents such as inhibitors of the Z-DNA binding proteins in poxviruses. This work also calls for careful chemical and biological characterization of drug leads obtained from chemical screens to avoid the identification of irrelevant chemical structures and to avoid the interference caused by direct interactions between the chemicals being screened and the luciferase reporter used in screening assays. Public Library of Science 2011-03-24 /pmc/articles/PMC3063779/ /pubmed/21455295 http://dx.doi.org/10.1371/journal.pone.0017883 Text en This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Pang, Yuan-Ping Park, Jewn Giew Wang, Shaohua Vummenthala, Anuradha Mishra, Rajesh K. McLaughlin, John E. Di, Rong Kahn, Jennifer Nielsen Tumer, Nilgun E. Janosi, Laszlo Davis, Jon Millard, Charles B. Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach |
title | Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach |
title_full | Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach |
title_fullStr | Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach |
title_full_unstemmed | Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach |
title_short | Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach |
title_sort | small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstop approach |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063779/ https://www.ncbi.nlm.nih.gov/pubmed/21455295 http://dx.doi.org/10.1371/journal.pone.0017883 |
work_keys_str_mv | AT pangyuanping smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT parkjewngiew smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT wangshaohua smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT vummenthalaanuradha smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT mishrarajeshk smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT mclaughlinjohne smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT dirong smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT kahnjennifernielsen smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT tumernilgune smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT janosilaszlo smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT davisjon smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach AT millardcharlesb smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach |